Bayer Group To Intensify Health Care Investment In China
This article was originally published in PharmAsia News
Bayer Group China recently revealed that the group will increase investment for its three business sectors-m aterial science, health care and crop science-over the next few years. The proportion of allocation will depend on the market development strategy under preparation and upcoming policies in China. The group will step up efforts in health care while it will slow down the pace for material science, currently its largest and most established sector in China. Besides importing technology, Bayer's health care in China will actively look for acquisitions or mergers, and expand funding in drug labs and clinical trials. In addition, the firm plans to launch about 20 medicines in China within the next five years. (Click here for more - Chinese Language)
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
Deal snapshot: Resolving a loose end from its 2014 buyout of Auxilium, Endo acquires all rights to Xiaflex, along with approved cellulite therapy Qwo.